Evidence map›Paper›PMID 38328097›Full record

ArticlebioRxiv : the preprint server for biology2024

The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir.

Tung Dinh, Zahira Tber, Juan S Rey, Seema Mengshetti, Arun S Annamalai, Reed Haney, Lorenzo Briganti, Franck Amblard, James R Fuchs, Peter Cherepanov and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Tung DinhDivision of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-5141-3281
Zahira TberCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Juan S ReyDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware, USA.
Seema MengshettiCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Arun S AnnamalaiDivision of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Reed HaneyDivision of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Lorenzo BrigantiDivision of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Franck AmblardCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
James R FuchsCollege of Pharmacy, The Ohio State University, Columbus, Ohio, United States.
Peter CherepanovChromatin Structure & Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-0634-538X
Kyungjin KimST Pharm Co., Ltd., Seoul, South Korea.
Raymond F SchinaziCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Juan R PerillaDepartment of Chemistry and Biochemistry, University of Delaware, Newark, Delaware, USA.
Baek KimCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Mamuka KvaratskheliaDivision of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-3800-0033
Emory University · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Delaware · USPharming Group (Netherlands) · NLThe Francis Crick Institute · GBThe Ohio State University · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in DelawareP20GM103446 · NIGMS · UNIVERSITY OF DELAWARE · PI Shawn W Polson · 2012 to 2026
$67.2M
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Alan N. Engelman · 2022 to 2026
$36.7M
Project 3. IntegrationU54AI170791 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGELA M. GRONENBORN, Tatyana Polenova · 2022 to 2026
$30.6M
Structural and Chemical Analysis of Highly Potent ALLINI PlatformR01AI141327 · NIAID · EMORY UNIVERSITY · PI Baek Kim · 2018 to 2026
$3.7M
Towards Suppression and Elimination of HIV in the CNSR01MH116695 · NIMH · EMORY UNIVERSITY · PI SCHINAZI, RAYMOND FELIX, TYOR, WILLIAM R · 2018 to 2022
$3.4M
Multimeric HIV-1 Integrase InhibitorsR01AI143649 · NIAID · UNIVERSITY OF COLORADO DENVER · PI KVARATSKHELIA, MAMUKA · 2019 to 2023
$2.5M
Data Management and Storage System for Shared Resource FacilitiesS10OD028725 · OD · UNIVERSITY OF DELAWARE · PI POLSON, SHAWN W · 2021 to 2021
$600k
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI141327NIAID NIH HHS R01 AI143649NIAID NIH HHS U54 AI170791NIAID NIH HHS U54 AI170855NIGMS NIH HHS P20 GM103446NIH HHS S10 OD028725NIMH NIH HHS R01 MH116695Wellcome Trust CC2058
6 · The paper itself

Abstract

Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are investigational antiretroviral agents which potently impair virion maturation by inducing hyper-multimerization of IN and inhibiting its interaction with viral genomic RNA. The pyrrolopyridine-based ALLINI pirmitegravir (PIR) has recently advanced into Phase 2a clinical trials. Previous cell culture based viral breakthrough assays identified the HIV-1

Indexed as

ALLINIantiretroviral drugHIV-1 integrasePirmitegravir

Identifiers

PMID38328097
PMCPMC10849636
OpenAlexW4391281874

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.